Trial Profile
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2021
Price :
$35
*
At a glance
- Drugs Fonadelpar (Primary)
- Indications Corneal disorders; Corneal injuries; Keratitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2015 Planned End Date changed from 1 Feb 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov
- 17 Jun 2015 Planned primary completion date changed from 1 Feb 2015 to 1 Dec 2015,as reported by ClinicalTrials.gov